Options for tackling antibiotic resistance

The growing threat of antibiotic resistance has accelerated regulatory, policy and funding initiatives over recent years, leading to a wave of new innovations in the area. In this webcast, experts from several companies in the field return to examine what is being done to tackle the impending antibiotic resistance crisis. A range of approaches include antibiotic-resistance breakers, macrocycles and other antibiotic classes for infections caused by key pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus are presented by the companies.

The webcast will also include a new and extended roundtable discussion and a Q&A section to allow you to participate and ask the speakers how they intend to tackle the emerging antibiotic resistance crisis.

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

Webcast sponsors retain sole responsibility for content.

Dr. Marc Lemonnier
Co-founder and CEO
View Presenter Biography
Dr. Prabhavathi Fernandes
Founder, President and CEO
Cempra Inc.
View Presenter Biography
Professor Anthony R.M. Coates
Founder and Chief Scientific Officer
Helperby Therapeutics
View Presenter Biography
Dr. David Huang
Chief Medical Officer
Motif Bio
View Presenter Biography
Dr. Glenn Dale
Head of Early Development, Antimicrobials
View Presenter Biography
Moderator: Raveena Bhambra
BioPharma Dealmakers

Sponsored by:



Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)